GX-E4
ApprovedA long-acting treatment for anaemia in chronic kidney disease, approved in Indonesia in October 2023 for non-dialysis patients, with a Phase 3 trial in dialysis patients under way in Europe.
FROM PUBLIC EVENTS · 2026-11-18
Pipeline reshaping Alongside long-acting protein therapeutics, it is presenting targeted protein degradation candidates at successive conferences. Also seen: Early clinical · first deals
Roles often seen at this stageResearch & development · BD & licensing · Clinical & PV
A biotech company developing long-acting protein therapeutics and targeted protein degradation (bioPROTAC) candidates.
A long-acting treatment for anaemia in chronic kidney disease, approved in Indonesia in October 2023 for non-dialysis patients, with a Phase 3 trial in dialysis patients under way in Europe.
A bioPROTAC candidate that degrades SOX2, with preclinical lung cancer data presented at AACR 2026 and WCLC 2026.
A diabetes and obesity candidate licensed to a Chinese partner, which has completed Phase 2 and entered Phase 3.
Gave an oral presentation of preclinical GX-BP1 lung cancer data at WCLC 2026.
Presented preclinical GX-BP1 data in a poster at AACR 2026.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.